# Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

> **NCT00430118** · PHASE3 · COMPLETED · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 4559 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** asparaginase
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** prednisone
- **DRUG:** thioguanine
- **DRUG:** vincristine sulfate
- **DRUG:** vindesine
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00430118
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 4559 (ACTUAL)
- **Last updated:** 2013-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430118, "Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00430118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*